Showing 4971-4980 of 7518 results for "".
- From EADV: Temtokibart Shows Sustained Efficacy in AD; New DELTA TEEN Datahttps://practicaldermatology.com/news/from-eadv-temtokibart-shows-sustained-efficacy-in-ad-new-delta-teen-data/2483428/LEO Pharma announced data from several important trials and presented updates on delgocitinib LEO Pharma presented phase 2b data for its investigational agent temtokibart (LEO 138559) at the 2025 European Academy of Dermatolo
- LEO To Focus on New Data for CHE, AD, and PsO at EADV 2025https://practicaldermatology.com/news/leo-to-present-data-on-che-ad-and-pso-at-eadv-2025/2483384/LEO Pharma has unveiled its largest-ever scientific program for presentation at the 2025 European Academy of Dermatology and Venereology (EADV) Congress, chronic hand eczema (CHE), atopic dermatitis (AD), and plaque psoriasis, along with updates on investigational a
- NB-UVB Phototherapy Effective for Psoriasis in Skin of Colorhttps://practicaldermatology.com/news/nb-uvb-phototherapy-effective-for-psoriasis-in-skin-of-color/2483263/A new systematic review and meta-analysis confirms that narrowband ultraviolet B (NB-UVB) phototherapy is effective for psoriasis in patients with skin of color, underscoring its role as a valuable treatment option despite the widespread adoption of biologics and systemic agents.
- Skin Microbiome and Aging: Connected for the Long Haul?https://practicaldermatology.com/news/skin-microbiome-and-aging-connected-for-the-long-haul/2483286/The skin microbiome is not just a passive reflection of age, but in fact may be a key player in how skin ages and its ability to resist decline. During her presentation on the intersection of microbiomes and skin aging at the 2025 Science of Skin Summit in Austin, TX, Julia Oh, PhD, a prof
- Early Childhood Stress Tied to Psoriasis Riskhttps://practicaldermatology.com/news/early-childhood-stress-tied-to-psoriasis-risk/2483262/A prospective cohort study from Sweden suggests that early childhood stress, particularly disruptions in family structure, may increase the risk of developing psoriasis later in life. The research, published in the Journal of Investigative Dermatology
- HS TRUTHS Video Series Centers Patient Experiencehttps://practicaldermatology.com/news/hs-truths-video-series-centers-patient-experience/2483232/Incyte announced this week that it has launched HS TRUTHS, a new disease education initiative aiming to elevate awareness of the lived experiences of individuals with hidradenitis suppurativa (HS).
- Arcutis Seeks FDA Greenlight to Expand ZORYVE for Children Under 6https://practicaldermatology.com/news/arcutis-seeks-fda-greenlight-to-expand-zoryve-for-children-under-6/2483230/Arcutis Biotherapeutics has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) to expand the indication of ZORYVE® (roflumilast) cream 0.3% for the treatment of plaque psoriasis in children aged 2 to 5, according to
- Analysis: GLP-1 Receptor Agonists Linked with Reduced Surgical/Hospitalization Burden in HShttps://practicaldermatology.com/news/analysis-glp-1-receptor-agonists-reduced-surgical-and-hospitalization-burden-in-hs/2483172/New real-world data suggest that glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are linked with reduced surgical interventions and hospitalizations in patients with hidradenitis suppurativa (HS). Researchers using real
- Bimekizumab Achieves Dual Clearance of Nail and Skin Psoriasishttps://practicaldermatology.com/news/bimekizumab-achieves-dual-clearance-of-nail-and-skin-psoriasis/2483170/In pooled analyses of phase III and IIIb trials, bimekizumab was associated with significantly higher rates of complete clearance of both skin and nail psoriasis compared to adalimumab, ustekinumab, and secukinumab in patients with moderate-to-severe plaque psorias
- Study: Tralokinumab Demonstrates Durable Response, High Retention in AD Patientshttps://practicaldermatology.com/news/tralokinumab-shows-strong-one-year-results-in-real-world-ad-study/2483171/The long-term use of tralokinumab in adults with moderate-to-severe atopic dermatitis (AD). Over a 52-week period, the IL-13 inhibitor demonstrated clinically meaningful and sustained improvements across multiple outcome measures, with a favorable safety profile and